Biotechnology Companies in Sweden

Apoglyx is a pre-clinical stage biotech company with the aim to develop a small molecule therapy for sepsis, and further indications, based on inhibition of Aquaporin-9. Apoglyx was founded based on research from Aarhus University (DK), Aalborg University (DK), and Lund University (S).

Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biological properties of professional antigen presenting cells. Backed by Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden, Asgard Therapeutics aims to build a pipeline of personalized cancer immunotherapies optimized to each unique patient.

Our ambition is to play a key role in tackling climate change, by enabling green chemistry for every industry. We do this by creating the most general and efficient technology platform for chemical production that the world has ever seen. That’s a big claim, but we can stand behind it. By bio-upgrading the chemical industry with our cell-free biomanufacturing platform, we can produce the products that modern society relies on in a truly sustainable way. The technology platform utilises nature’s catalysts, enzymes, by combining the power of biology with the efficiency of the chemical industry in a best-of-both-worlds solution. EnginZyme is recognised as a Technology Pioneer by World Economic Forum and backed by Sofinnova Partners, Industrifonden, SEB Greentech VC, Bunge Ventures, Almi Invest GreenTech Fund, and Navigare Ventures.

Elsa Science strives to contribute to a future where chronic disease is minimized. Where people who are diagnosed can reach optimal health sooner and live a new life faster, and to its full potential. Elsa Science was established in 2017 by a team of influential scientists and award winning designers who have a passion to improve the health of people living with chronic disease. Driven by science, self-reported patient data, and individualized care, and through meaningful content and design, Elsa Science aims to make science accessible and put it in the hands of the people living with a chronic disease. Providing motivation and education through two tools - the Elsa Science Self-care app and Clinical Dashboard, bring patients and families closer together with healthcare providers through seamless data sharing. Our digital solution provides a powerful communication tool for a greater good, to better manage the illness, improve healthcare, and empower the individual to proactively self-care.

Elypta is a Swedish molecular diagnostics company focused on reducing cancer mortality through early detection. Elypta is pioneering a metabolism-based liquid biopsy and measures the GAGome – system biomarkers of tumor metabolism. Machine learning algorithms are then used to detect signatures of cancer noninvasively. Elypta is advancing a broad clinical program across different cancers with the first indication expected to be early detection of recurrence in renal cell carcinoma. Several years of research in Nielsen lab at Chalmers University of Technology in Gothenburg, Sweden led to the founding of Elypta in May 2017 by Francesco Gatto and Jens Nielsen.

Gradientech is a Swedish biotech and diagnostics company dedicated to support the modern microbiology lab with state-of-the-art solutions to facilitate the workflow with time-critical samples. Our product QuickMIC® is an ultra-rapid system for antibiotic susceptibility testing (AST) of positive blood culture samples from sepsis patients. QuickMIC® is a scalable system with each instrument module analysing one sample against multiple antibiotics, well-suited for small and larger clinical laboratories. MIC values are reported in as short as 2 hours, making it more rapid than any other diagnostic system for phenotypic AST on the market. Gradientech’s technology combines microfluidics with live cell imaging to study cell responses in a linear concentration gradient. Our technology is a perfect match for many biological applications. Gradientech holds an ISO13485 certification.

The forest is a renewable resource. Lignin is a by-product from the pulping industry. Globally 80 million tonnes is processed in the pulping industry, making it the largest natural by-product on earth. Today, 99% of the produced lignin is burnt for its energy value. We, at Lignin Industries, convert lignin so it can be blended with virgin and recycled thermoplastics creating new types of bioplastics. For every 1 kg of fossil based plastics replaced by RENOL® we decrease CO₂ up to 6 kgs released into the atmosphere. We can provide the plastic industry with large amounts of granulates for several market segments ranging from packaging, agricultural films and injection moulding pieces. Lignin Industries is one of the few selected companies among 232 proposals to be supported by the European Union Innovation Fund that will co-fund Lignin Industries by financing the expansion of the first-of-its-kind large-scale production site, located in Sweden. The funding was given under the call “Innovation Fund” with the aim to support projects demonstrating highly innovative technologies and products that have a significant potential to reduce greenhouse emissions.

At Mycorena, we are on a mission to significantly change how we produce and consume food. We believe in the power of fungi and want to pave the way for a sustainability revolution by offering the industry scalable, high-quality products. Through innovative technology, we develop sustainable mycelium-based solutions for the food industry. Our flagship product Promyc is a proprietary vegan mycoprotein with superior nutritional value in protein, fibre, vitamins, and minerals. With a neutral taste and a satisfying fibrous texture, Promyc offers the most demanded qualities in the alternative protein segment. What originated as a research project has grown into one of the fastest-growing companies in the industry. Since our founding in 2017, we have scaled from a small lab to Scandinavia’s largest demo production facility for mycoprotein. We are expanding further as we prepare to commence commercial production in our new Promyc Production Plant, the first of its kind in Scandinavia. Our vision is to be world-leading in fungi-based technology and drive the change in the food system for a sustainable tomorrow. The future of food is now.

Navinci (formerly Olink Bioscience), has a proud history of inventing analytic technologies for nucleic acids and proteins, identifying commercial opportunities and bringing successful products to the market to serve scientist in research and drug development. Founded in 2004 on the breakthrough innovations by Ulf Landegren and colleagues at Uppsala University, the company has directly marketed a wide range of products including the Duolink in situ protein detection product line, which was acquired by Sigma-Aldrich in 2016. Navinci has also launched several daughter companies such as Olink Proteomics (noted Nasdaq NY: OLK) for high-throughput protein analysis in blood, Q-linea (noted on Nasdaq) focusing on counteracting antibiotic resistance in sepsis, and Halogenomics (acquired by Agilent) in target selection for next generation sequencing. Moreover, the company has outlicensed IP rights to several leading international life science companies. Navinci holds a broad and growing patent portfolio utilizing oligonucleotide-conjugated antibodies for detection of proteins and their interactions. From our base in Uppsala, Sweden, Navinci contributes to improve human health by serving scientist with sharp and tailored tools to study proteins and their interactions in order to understand human biology and develop better drugs.

Melt&Marble’s mission is to become an enabler for the alternative protein industry by providing it with the best and tastiest fats. We do this by using precision fermentation to produce animal fats without the animal. By engineering microbial metabolism, we can dictate the structure and properties of the fats that our microbes are producing, allowing us to mimic any fat structure, as well as create completely new and better fats. The result: tastier plant-based foods, for consumers and the planet!

Ziccum's ambient drying technology LaminarPace opens up unique thermostable formulation possibilities for next-generation biomolecules - from vaccines to protein therapeutics.

TIGERQ is a Cancer Genomics Software startup in Lund, Sweden. We are commercializing a patented and extremely accurate sequencing analysis for currently unaddressed complex genetic changes (which drive 73% of all cancers), applicable to a €2.8B cancer genomic software market.

ArgusEye provides innovative sensor systems based on nanoplasmonic detection for real-time monitoring of biological systems and processes.

We are providing electronically activated purification of biomolecules for biopharmaceutical and protein production. By utilizing our patent-pending invention, we build functionalized polymer surfaces that can with high specificity and high capacity capture and release biomolecules at the press of a button. Making today's complex biopharmaceutical and protein manufacturing simpler, more effective, and digital.

Atley’s automated production module allows for a standardised and reproducible production of the pharmaceuticals used in Targeted Alpha Therapy, a promising treatment for disseminated cancer. The module will enhance clinical research in this field and is essential in order to enable the future treatment of cancer patients using this method. Targeted Alpha Therapy has the potential to improve and save millions of lives. For this to happen, Atley's technology is needed.

Norbite transforms plastic waste into sustainable goods by means of an insect-based biorefinery. The selected insect, Galleria mellonella, possess the extraordinary capacity to naturally digests plastic. Norbite took advantage of this feeding specificity of G. mellonella and has developed a proprietary vertical farming technology to enable the insects to perform at industrial scale. To produce sustainable goods, thus obtained larvae are bio-refined to get proteins, for food and feed; antimicrobial peptides (AMPs) - to fight multidrug resistant bacteria (MDR); elicitors – to reinforce natural plants’ defences and avoid the utilisation of pesticides; and even the dejections of the insects are used as biofertilizers, making this process a perfect example of circular economy.

We produce uniquely functional materials that are good for the planet. Our mission is to be the world-leading producer of advanced materials from algae and a driving force towards a circular and bio-based industry. We are the first company in the world to cultivate and sell diatom algae shells. We call the material Algica®. Algica® is a porous silica with unique light altering, absorptive and binding properties that are unmatched by synthetic materials. Algica® is today used as a top-performing and certified organic personal care ingredient. Products with Algica® has today been launched in the Nordics, US and Australia. Read more about the use of Algica in personal care applications at www.algica.com Algica® can also make silicon solar panels at least 4% more efficient and DSSC 38% more efficient. Each kg Algica® used in solar panels reduces C02 emissions with at leasts 200 tons according to WWF. The production is circular and we aim to make it as environmentally friendly as possible. The algae clean nutrient rich water from a land-based fish farm, and absorb CO2 and key nutrients that can be made into sustainable fish feed.

Building accurate, accessible and affordable disease diagnostics to improve global health.